帕博利珠单抗治疗皮肤恶性黑色素瘤的临床效果

doi:10.20047/j.issn1673-7210.2022.35.24

摘要
图/表
参考文献(28)
相关文章 (15)

全文: PDF (784 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探究帕博利珠单抗治疗皮肤恶性黑色素瘤的临床效果。方法选取南京医科大学附属淮安第一医院2019年3月至2021年1月收治的64例皮肤恶性黑色素瘤患者作为研究对象，以随机数字表法将其分为研究组和对照组，各32例。对照组予以外科手术治疗联合化疗，研究组在对照组基础上联合帕博利珠单抗治疗。治疗4个月后评估两组临床疗效、生存质量、不良反应，并跟踪随访1年。结果研究组疾病控制率高于对照组，差异有统计学意义（P＜0.05），两组临床缓解率比较差异无统计学意义（P＞0.05）。治疗后，两组社会功能、心理功能、躯体功能评分较治疗前升高，且研究组高于对照组（P＜0.05）。研究组不良反应总发生率高于对照组（P＜0.05）。研究组生存曲线高于对照组（P＜0.05）。结论帕博利珠单抗在皮肤恶性黑色素瘤治疗中可显著提高疾病控制率，可能出现甲状腺功能异常等不良反应风险，且患者可耐受。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	姚宇驰1 吴敏2▲

关键词 ：皮肤恶性黑色素瘤, 外科手术, 帕博利珠单抗, 安全性

Abstract：Objective To explore the clinical effect of Pabolizumab in the treatment of cutaneous malignant melanoma. Methods A total of 64 patients with cutaneous malignant melanoma admitted to the Huai’an First Affiliated Hospital of Nanjing Medical University from March 2019 to January 2021 were selected as the research objects, and they were divided into study group and control group by random number table method, with 32 cases in each group. The control group was treated with surgery combined with chemotherapy, and the study group was treated with Pabolizumab on the basis of the control group. After four months of treatment, the clinical efficacy, quality of life, and adverse reactions of the two groups were evaluated, and the 1-year was recorded by follow-up. Results The disease control rate of the study group was higher than that of the control group, and the difference was statistically significant (P＜0.05); there was no significant difference in clinical remission rate between the two groups (P＞0.05). After treatment, the scores of social function, psychological function, and physical function of the two groups were higher than those before treatment, and the study group was higher than the control group (P＜0.05). The total incidence of adverse reactions in the study group was higher than that in the control group (P＜0.05). The survival curve of the study group was higher than that of the control group (P＜0.05). Conclusion Pabolizumab can significantly improve the disease control rate in the treatment of cutaneous malignant melanoma. There may be adverse reactions such as abnormal thyroid function， but the patients can tolerate it.

Key words： Cutaneous malignant melanoma Surgery Pembrolizumab Safety

基金资助:江苏省高校哲学社会科学研究一般项目（2020 SJA0089）。

通讯作者: ▲通讯作者

作者简介: 姚宇驰（1991.7-），男，硕士；研究方向：烧伤整形。

引用本文:

姚宇驰1 吴敏2▲. 帕博利珠单抗治疗皮肤恶性黑色素瘤的临床效果[J]. 中国医药导报, 2022, 19(35): 106-109,134.
YAO Yuchi1 WU Min2▲. Clinical effect of Pabolizumab on cutaneous malignant melanoma. 中国医药导报, 2022, 19(35): 106-109,134.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2022.35.24 或 https://www.yiyaodaobao.com.cn/CN/Y2022/V19/I35/106